Cargando…

Boosting BNT162b2 vaccine efficacy in CLL

Detalles Bibliográficos
Autores principales:	Bhat, Seema A., Woyach, Jennifer A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Blood Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812057/ https://www.ncbi.nlm.nih.gov/pubmed/35113151 http://dx.doi.org/10.1182/blood.2021014903

Ejemplares similares

Vaccination against COVID-19: a challenge in CLL
por: Eichhorst, Barbara
Publicado: (2021)

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
por: Enßle, Julius C., et al.
Publicado: (2022)

Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
por: Oh, Bernice Ling Zhi, et al.
Publicado: (2022)

CLL and COVID-19: light at the end of the tunnel?
por: Scarfò, Lydia, et al.
Publicado: (2022)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
por: Blixt, Lisa, et al.
Publicado: (2022)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
por: Silvestris, Nicola
Publicado: (2021)

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
por: Roeker, Lindsey E., et al.
Publicado: (2021)

Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
por: Herishanu, Yair, et al.
Publicado: (2022)

Curing CLL: one clone at a time
por: Aslan, Burcu, et al.
Publicado: (2022)

Vaccinations and ITP: keep on track(ing)
por: Bakchoul, Tamam, et al.
Publicado: (2022)

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report
por: Cuneo, Antonio, et al.
Publicado: (2020)

VITT(al) insights into vaccine-related clots
por: Strich, Jeffrey R., et al.
Publicado: (2021)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Danger ahead: COVID-19 infections after vaccination
por: Greenberger, Lee M., et al.
Publicado: (2022)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
por: Iketani, Sho, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Why B(-)other? About the gap of unknowns in ALL
por: Fioretos, Thoas
Publicado: (2022)

1559O Efficacy and toxicity of BNT162b2 vaccine in cancer patients
por: Ben-Aharon, I., et al.
Publicado: (2021)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
por: Rammauro, Florencia, et al.
Publicado: (2022)

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
por: Hyak, Jonathan M., et al.
Publicado: (2022)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
por: Wang, Bei, et al.
Publicado: (2021)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
por: Shimazawa, Rumiko, et al.
Publicado: (2021)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022)

Tet2 helps blood cells balance in air
por: Chute, John P.
Publicado: (2022)

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Tenbusch, Matthias, et al.
Publicado: (2021)

Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months
por: Low, Ee Vien, et al.
Publicado: (2022)

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
por: Behrens, Georg M. N., et al.
Publicado: (2022)

Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy
por: Jedicke, Nils, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ke8egh1ltlv5e1rjighofdat3l